St Louis University, St Louis, MO, USA.
Research Department, HealthCore Inc, Wilmington, DE, USA.
J Clin Lipidol. 2017 Jul-Aug;11(4):891-900. doi: 10.1016/j.jacl.2017.04.120. Epub 2017 May 24.
Statin therapy is recommended for reducing atherosclerotic cardiovascular disease (ASCVD) risk. Significant risk can remain because of insufficient clinical response or statin intolerance. Proprotein convertase subtilisin/kexin type-9 (PCSK9) therapy lowers low-density lipoprotein cholesterol and has recently been shown to lower ASCVD events.
The aim of the study was to assess the barriers and challenges experienced with the access and approval reimbursement process for PCSK9 inhibitor prescriptions.
In 2016, the National Lipid Association conducted an online survey on PCSK9 inhibitor use and barriers to prescription among experienced healthcare workers who provide care to high-risk patients with ASCVD or familial hypercholesterolemia (FH).
There were 434 respondent healthcare workers with extensive experience in treating lipid disorders. PCSK9 inhibitors are considered by 71.3% of respondent providers with statin-intolerant patients. There were high rates (>85%) of initial denial. The major barriers to approvals were insurer processes, provider documentation (inadequate documentation of maximally tolerated statin dose, diagnostic criteria for FH, number of statins failed if statin intolerant and most recent low-density lipoprotein cholesterol), and administrative burden (time, staff, paperwork, and appeals). Provider approval rates for getting ≥75% patients approved were higher for FH (43%) than for ASCVD patients (36%). Among providers with good approval rates, documentation was the most critical factor. Barriers more difficult to overcome include perceived higher threshold requirements by payers, drugs not on formulary, and drug costs.
Healthcare providers encounter significant barriers to PCSK9 inhibitor prescriptions; many of these are related to documentation issues and can be overcome with checklists, staff support, and experience.
他汀类药物治疗被推荐用于降低动脉粥样硬化性心血管疾病(ASCVD)风险。由于临床反应不足或他汀类药物不耐受,仍存在较大风险。前蛋白转化酶枯草溶菌素/克那霉 9(PCSK9)治疗可降低低密度脂蛋白胆固醇,最近已被证明可降低 ASCVD 事件的发生。
本研究旨在评估获得和批准 PCSK9 抑制剂处方的准入和报销过程中存在的障碍和挑战。
2016 年,国家脂质协会对具有 ASCVD 或家族性高胆固醇血症(FH)高危患者治疗经验的医疗保健工作者进行了一项关于 PCSK9 抑制剂使用和处方障碍的在线调查。
共有 434 名经验丰富的医疗保健工作者回复了该调查,他们在治疗脂质紊乱方面经验丰富。71.3%的他汀类药物不耐受患者的提供者认为 PCSK9 抑制剂是可考虑的。初始拒绝率很高(>85%)。批准的主要障碍是保险公司的流程、提供者的文件(最大耐受剂量他汀类药物的文件不足、FH 的诊断标准、不耐受他汀类药物的他汀类药物数量以及最近的低密度脂蛋白胆固醇)和行政负担(时间、人员、文书工作和上诉)。对于获得≥75%患者批准的提供者,FH 患者(43%)的批准率高于 ASCVD 患者(36%)。在批准率较高的提供者中,文件是最重要的因素。更难克服的障碍包括支付方认为要求更高、药物未列入处方和药物费用。
医疗保健提供者在开具 PCSK9 抑制剂处方时遇到了重大障碍;其中许多与文件问题有关,可以通过检查表、人员支持和经验来克服。